Research&Development
With our experienced R&D team, profound insights into ADC design, and strong execution capabilities, we have created four leading ADC technology platforms: DITAC, DIBAC, DIMAC, and DUPAC, to break through the boundaries of ADC therapy. Our technology platform serves as the foundation for continuous innovation and value creation, and its value and diversity have been validated in our pipeline assets and recognized by multinational pharmaceutical partners.
DB-1303
/BNT323
HER2
Mainland China, Hong Kong, Macau
DB-1311/BNT324
B7-H3
Mainland China, Hong Kong, Macau (U.S.: Option to Co-develop and Co-commercialize)
DB-1310
HER3
Global
DB-1305 /BNT325
TROP2
Mainland China, Hong Kong, Macau
Note: 1. Expected trial completion date on ClinicalTrials.gov
Mono = Monotherapy, Combo = Combination Therapy, IND= Investigational New Drug, NCT = National Clinical Trial, ADC = Antibody-drug Conjugate, HER2 = Human Epidermal Growth Factor Receptor 2, HER2-expressing = HER2 Status of Tumor Cells Identified with a Test Score of IHC 1+ or Above, EC = Endometrial Cancer, HR+ = Hormone Receptor Positive, HER2-low=HER2 Status of Tumor Cells Identified with a Test Score of IHC 1+ or IHC 2+/ISH-, BC = Breast Cancer, Chemo = Chemotherapy, HER2+ = HER2 Status of Tumor Cells Identified with a Test Score of Either IHC 3+ or IHC 2+/ISH+, OC = Ovarian Cancer, CRC = Colorectal Cancer, SCLC = Small Cell Lung Cancer, NSCLC = Non-small Cell Lung Cancer, HER3 = Human Epidermal Growth Factor Receptor 3, EGFRm = EGFR Mutant, TKI = Tyrosine Kinase Inhibitor, KRASm = Kirsten Rat Sarcoma Virus Mutant, CRPC = Castration-resistant Prostate Cancer, HNSCC = Head and Neck Squamous Cell Carcinoma, BTC = Biliary Tract Cancer, TROP2= Human Trophoblast Cell-surface Antigen 2, CC = Cervical Cancer, TNBC = Triple-negative Breast Cancer, PD-L1 = PD-1 Ligand 1, VEGF = Vascular Endothelial Growth Factor, bsAb = Bispecific Antibody, EGFR = Epidermal Growth Factor Receptor, BDCA2 = Blood Dendritic Cell Antigen 2, MOA = Mechanism of Action, SLE = Systemic Lupus Erythematosus, CLE = Cutaneous Lupus Erythematosus, FDA = U.S. Food and Drug Administration, NMPA = National Medical Products Administration of the PRC
DualityBio's commercialization strategy will integrate a variety of business models, including licensing, co-promotion, and direct sales, to flexibly adapt to different market environments and maximize product value and market coverage.
Currently, the company is fully committed to building a professional and highly efficient core commercialization team, covering key functional areas such as market access, marketing, post-launch medical support, channel operation management, and partnership management. This team will be responsible for formulating and implementing commercialization strategies in the Greater China region. The team is dedicated to establishing and strengthening core commercialization capabilities in market access, distribution network development, and brand strategy planning in the Greater China region, laying a solid foundation for the successful launch and market promotion of products. Meanwhile, we have established close cooperation with outstanding domestic partners, leveraging their professional contract sales organization (CSO) capabilities to fully advance the launch preparations for our first commercialized product, ensuring that the product can quickly and accurately reach the target market and customer base.
In markets outside the Greater China region, we have licensed the rights to our first commercialized product to excellent overseas partners. By leveraging their extensive resources and expertise in the international market, we aim to accelerate the global commercialization of the product, further expand our market footprint, and enhance our brand's international influence.
Scan the code to follow DualityBio official wechat
Phone：021-2601 8730
Address：Full floor, 11th floor, tower a, Datang International Plaza,China
Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai
